Valsartan + Hydrochlorothiazide

Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: Per combination tablet contains valsartan/hydrochlorothiazide: 80/12.5 mg; 160/12.5 mg; 160/25 mg; 320/12.5 mg; 320/25 mg: Initially, 80/12.5 mg once daily, titrate dose gradually according to response, up to 320/25 mg.
Renal Impairment
<30Not recommended.
Chống chỉ định
Hypersensitivity to valsartan, hydrochlorothiazide or sulphonamides. Severe hepatic impairment, creatinine clearance <30ml/min, anuria, cirrhosis, biliary obstruction, conditions where there is increased potassium loss (e.g. salt losing nephropathies and pre-renal impairment of kidney function), refractory hypokalaemia, hyponatraemia, hypercalcaemia, hyperuricaemia, history of gout and uric acid stones, untreated Addison's disease. Pregnancy and lactation.
Thận trọng
DM, postsympathectomy patients. May exacerbate SLE. Monitor serum potassium regularly. Observe for signs of fluid or electrolyte imbalance. Discontinue before testing for parathyroid function. May affect ability to drive or operate machinery. Elderly.
Phản ứng phụ
Headache, asthenia, fatigue, dizziness, somnolence, insomnia, orthostatic hypotension, paraesthesia, nasopharyngitis, tachycardia, palpitations, tinnitus, vertigo, dyspepsia, diarrhoea, flatulence, dry mouth, nausea, vomiting, abdominal pain, peripheral oedema, pyrexia, increased BUN, elevated LFT, anxiety, erectile dysfunction, glucose intolerance, increased serum cholesterol, triglycerides, uric acid. Electrolyte imbalances e.g. hypomagnesaemia, hypercalcaemia, hyponatraemia, hypochloraemic alkalosis.
Quá liều
Symptoms: Hypotension, tachycardia, bradycardia, circulatory collapse, electrolyte abnormalities (e.g. hypokalaemia, hypochloremia, hyponatremia, dehydration). Management: Treatment is symptomatic and supportive. Effectiveness of haemodialysis is unknown.
Tương tác
Increased antihypertensive effect with other antihypertensive drugs. Monitor potassium frequently if used with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or drugs that may affect potassium levels (e.g. heparin, ciclosporin, drospirenone, amphotericin, corticosteroids, carbenoxolone). Reduced antihypertensive effect of valsartan and increased risk of renal impairment with NSAIDs. May reduce renal clearance of cytotoxic drugs (e.g. cyclophosphamide, methotrexate). Increased serum calcium with vitamin D or calcium salts.
Potentially Fatal: Increased lithium levels with valsartan, monitor lithium levels. Increased risk of cardiac arrhythmia with dofetilide, avoid use.
Lab Interference
Thiazides may decrease serum protein bound iodine levels.
Tác dụng
Description: Valsartan is an angiotensin II receptor antagonist and reduces blood pressure by blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide is a thiazide diuretic.
Onset: Hyopotensive effect of valsartan: 2hr. Diuresis effect of hydrochlorothiazide: 2 hr.
Duration: Hypotensive effect of valsartan: 24 hr. Diuresis effect of hydrochlorothiazide: 6-12 hr.
Absorption: Valsartan: Rapidly absorbed, bioavailability 23%, peak plasma concentration occur 2-4 hr. Hydrochlorothiazide: Rapidly absorbed, bioavailability: 65-70%.
Distribution: Valsartan: Protein binding 94-97%, mainly to serum albumin, volume of distribution: 17 L. Hydrochlorothiazide: Preferentially bound to red blood cells, crosses placenta and excreted into breast milk.
Metabolism: Valsartan: Not significantly metabolised.
Excretion: Valsartan: Excreted mainly as unchanged drug in faeces (70%) and urine (30%), terminal half life 5-9 hr. Hydrochlorthiazide: Excreted mainly unchanged in urine, plasma half life 5-15 hr.
Bảo quản
Store between 15-30°C.
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Valsartan + Hydrochlorothiazide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Angiotan-H
  • Carwin HCT
  • Gliovan-HCTZ
  • Valsgim-H
  • Valzaar
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in